{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,4]],"date-time":"2026-02-04T19:41:54Z","timestamp":1770234114090,"version":"3.49.0"},"reference-count":43,"publisher":"Oxford University Press (OUP)","issue":"1170","license":[{"start":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T00:00:00Z","timestamp":1741824000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"funder":[{"name":"NIHR_CHPR"},{"DOI":"10.13039\/501100000272","name":"National Institute for Health Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"name":"The Centre for Health Protection Research","award":["108299"],"award-info":[{"award-number":["108299"]}]},{"name":"SIRIC Montpellier Cancer","award":["INCa_Inserm_DGOS_12553"],"award-info":[{"award-number":["INCa_Inserm_DGOS_12553"]}]},{"DOI":"10.13039\/501100000272","name":"National Institute for Health and Care Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000272","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014461","name":"Biomedical Research Centre","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014461","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NHS Foundation Trust"},{"DOI":"10.13039\/501100000027","name":"Institute of Cancer Research","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000027","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006662","name":"NIHR","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006662","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000276","name":"Department of Health and Social Care","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000276","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,6,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Objectives<\/jats:title>\n                  <jats:p>Radiation-induced lymphocyte apoptosis (RILA) and chromosomal damage assays (CDA) are proposed predictors of radiotherapy (RT) adverse events (RTAE). This study evaluated RILA and CDA in patients undergoing different RT dose regimens for early breast (FAST trial) or prostate (CHHiP trial) cancer.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Consecutive patients were recruited from each trial. Fresh heparinized blood samples were analysed for RILA and CDA. The primary endpoint was time to first change in photographic breast appearance (FAST) or time to first grade \u22652 RTOG bladder or bowel toxicity (CHHiP). The secondary endpoint in FAST was breast fibrosis.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The dataset included 103 FAST and 297 CHHiP trial patients. No significant association of RILA with the primary endpoint was observed in the FAST trial. However, the risk of grade \u22652 breast fibrosis was lower in patients with RILA \u226524% compared to those with RILA \u226416% (P\u2009=\u2009.012). In the CHHiP trial, no significant associations were found between CDA after prostate RT outcomes. However, higher levels of micronuclei per cell were associated with a lower risk of grade \u22652 RTOG pelvic toxicities. The relative risk of developing grade \u22652 RTAE decreased for patients with RILA\u2009\u2265\u200924% but was not statistically significant.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>No association was found between RILA and photographic breast appearance. High RILA values were statistically associated with a lower risk of grade \u22652 breast fibrosis. In the CHHiP trial, most assays showed no association with pelvic toxicities.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Advances in knowledge<\/jats:title>\n                  <jats:p>RILA is confirmed as a potential predictor of breast fibrosis regarding fraction sizes.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/bjr\/tqaf056","type":"journal-article","created":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T19:05:31Z","timestamp":1741892731000},"page":"929-937","source":"Crossref","is-referenced-by-count":1,"title":["Radiation-induced lymphocyte apoptosis and chromosomic aberrations for prediction of toxicities in patients undergoing radical radiotherapy for breast or prostate cancers"],"prefix":"10.1093","volume":"98","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7533-2988","authenticated-orcid":false,"given":"David","family":"Azria","sequence":"first","affiliation":[{"name":"University Federation of Radiation Oncology of Mediterranean Occitanie, Montpelier Cancer Institute (ICM), Montpellier Cancer Research Institute (IRCM), University of Montpellier , 34298 Montpellier,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanne S","family":"Haviland","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research , SW7 3RP London,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Muriel","family":"Brengues","sequence":"additional","affiliation":[{"name":"University Federation of Radiation Oncology of Mediterranean Occitanie, Montpelier Cancer Institute (ICM), Montpellier Cancer Research Institute (IRCM), University of Montpellier , 34298 Montpellier,","place":["France"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Clare","family":"Griffin","sequence":"additional","affiliation":[{"name":"The Institute of Cancer Research Clinical Trials and Statistics Unit, The Institute of Cancer Research , SW7 3RP London,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayne","family":"Moquet","sequence":"additional","affiliation":[{"name":"Public Health England, Centre for Radiation, Chemical and Environmental Hazards , Chilton OX11 0RQ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen","family":"Barnard","sequence":"additional","affiliation":[{"name":"Public Health England, Centre for Radiation, Chemical and Environmental Hazards , Chilton OX11 0RQ,","place":["United Kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3954-2806","authenticated-orcid":false,"given":"David P","family":"Dearnaley","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research , London SM2 5NG,","place":["United kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Annie","family":"Gao","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research , London SM2 5NG,","place":["United kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lone","family":"Gothard","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research , London SM2 5NG,","place":["United kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kai","family":"Rothkamm","sequence":"additional","affiliation":[{"name":"Public Health England, Centre for Radiation, Chemical and Environmental Hazards , Chilton OX11 0RQ,","place":["United Kingdom"]},{"name":"Department of Radiotherapy & Radiation Oncology, University Medical Center Hamburg-Eppendorf, University Cancer Center Hamburg , 20251 Hamburg,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John R","family":"Yarnold","sequence":"additional","affiliation":[{"name":"Division of Radiotherapy and Imaging, The Institute of Cancer Research , London SM2 5NG,","place":["United kingdom"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,3,13]]},"reference":[{"key":"2025052713263508300_tqaf056-B1","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1053\/ejso.1999.0708","article-title":"Does cosmetic outcome from treatment of primary breast cancer influence psychosocial morbidity?","volume":"25","author":"Al-Ghazal","year":"1999","journal-title":"Eur J Surg Oncol"},{"key":"2025052713263508300_tqaf056-B2","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1016\/S1470-2045(15)00280-6","article-title":"Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"16","author":"Wilkins","year":"2015","journal-title":"Lancet Oncol"},{"key":"2025052713263508300_tqaf056-B3","doi-asserted-by":"crossref","first-page":"1425","DOI":"10.1056\/NEJMoa1606221","article-title":"Patient-reported outcomes after monitoring, surgery, or radiotherapy for prostate cancer","volume":"375","author":"Donovan","year":"2016","journal-title":"N Engl J Med"},{"issue":"Suppl 1","key":"2025052713263508300_tqaf056-B4","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1016\/j.critrevonc.2010.08.003","article-title":"Identifying patients at risk for late radiation-induced toxicity","volume":"84","author":"Azria","year":"2012","journal-title":"Crit Rev Oncol Hematol."},{"key":"2025052713263508300_tqaf056-B5","doi-asserted-by":"crossref","first-page":"E359","DOI":"10.1002\/ijc.29210","article-title":"Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012","volume":"136","author":"Ferlay","year":"2015","journal-title":"Int J Cancer"},{"key":"2025052713263508300_tqaf056-B6","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1016\/S0140-6736(12)60919-2","article-title":"Global burden of cancer in 2008: a systematic analysis of disability-adjusted life-years in 12 world regions","volume":"380","author":"Soerjomataram","year":"2012","journal-title":"Lancet"},{"key":"2025052713263508300_tqaf056-B7","doi-asserted-by":"crossref","first-page":"7426","DOI":"10.1158\/1078-0432.CCR-04-2634","article-title":"CD4 and CD8 T-lymphocyte apoptosis can predict radiation-induced late toxicity: a prospective study in 399 patients","volume":"11","author":"Ozsahin","year":"2005","journal-title":"Clin Cancer Res"},{"key":"2025052713263508300_tqaf056-B8","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/S1470-2045(10)70013-9","article-title":"Concurrent or sequential adjuvant letrozole and radiotherapy after conservative surgery for early-stage breast cancer (CO-HO-RT): a phase 2 randomised trial","volume":"11","author":"Azria","year":"2010","journal-title":"Lancet Oncol"},{"key":"2025052713263508300_tqaf056-B9","doi-asserted-by":"crossref","first-page":"1965","DOI":"10.1016\/j.ebiom.2015.10.024","article-title":"Radiation-induced CD8 T-lymphocyte apoptosis as a predictor of breast fibrosis after radiotherapy: results of the prospective multicenter French trial","volume":"2","author":"Azria","year":"2015","journal-title":"EBioMedicine"},{"key":"2025052713263508300_tqaf056-B10","doi-asserted-by":"crossref","first-page":"S256","DOI":"10.1016\/S0167-8140(19)30918-1","article-title":"Results of the prospective trial evaluating radiation-induced lymphocyte apoptosis and prostate RT","author":"Azria","year":"2019","journal-title":"Radiother Oncol"},{"key":"2025052713263508300_tqaf056-B11","doi-asserted-by":"crossref","first-page":"S2444","DOI":"10.1016\/S0167-8140(24)02014-0","article-title":"Radiation-induced CD8 T-lymphocyte apoptosis and pelvic toxicity after prostate radiotherapy: results of a prospective multicenter trial","author":"Riou","year":"2024","journal-title":"Radiother Oncol"},{"key":"2025052713263508300_tqaf056-B12","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/S0167-8140(02)00167-6","article-title":"Indicators of late normal tissue response after radiotherapy for head and neck cancer: fibroblasts, lymphocytes, genetics, DNA repair, and chromosome aberrations","volume":"64","author":"Borgmann","year":"2002","journal-title":"Radiother Oncol"},{"key":"2025052713263508300_tqaf056-B13","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/j.radonc.2003.10.001","article-title":"Individual radiosensitivity measured with lymphocytes may be used to predict the risk of fibrosis after radiotherapy for breast cancer","volume":"69","author":"Hoeller","year":"2003","journal-title":"Radiother Oncol"},{"key":"2025052713263508300_tqaf056-B14","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.radonc.2011.05.071","article-title":"Residual DNA and chromosomal damage in ex vivo irradiated blood lymphocytes correlated with late normal tissue response to breast radiotherapy","volume":"99","author":"Chua","year":"2011","journal-title":"Radiother Oncol"},{"key":"2025052713263508300_tqaf056-B15","doi-asserted-by":"crossref","first-page":"3261","DOI":"10.1200\/JCO.19.02750","article-title":"Ten-year results of FAST: a randomized controlled trial of 5-fraction whole-breast radiotherapy for early breast cancer","volume":"38","author":"Brunt","year":"2020","journal-title":"J Clin Oncol"},{"key":"2025052713263508300_tqaf056-B16","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1016\/S1470-2045(16)30102-4","article-title":"Conventional versus hypofractionated high-dose intensity-modulated radiotherapy for prostate cancer: 5-year outcomes of the randomised, non-inferiority, phase 3 CHHiP trial","volume":"17","author":"Dearnaley","year":"2016","journal-title":"Lancet Oncol"},{"key":"2025052713263508300_tqaf056-B17","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1016\/j.euo.2021.07.005","article-title":"Impact of hypofractionated radiotherapy on patient-reported outcomes in prostate cancer: results up to 5 yr in the CHHiP trial (CRUK\/06\/016)","volume":"4","author":"Staffurth","year":"2021","journal-title":"Eur Urol Oncol"},{"key":"2025052713263508300_tqaf056-B18","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1016\/j.clon.2008.03.017","article-title":"Evaluation of a method for grading late photographic change in breast appearance after radiotherapy for early breast cancer","volume":"20","author":"Haviland","year":"2008","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2025052713263508300_tqaf056-B19","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(13)70386-3","article-title":"The UK Standardisation of Breast Radiotherapy (START) trials of radiotherapy hypofractionation for treatment of early breast cancer: 10-year follow-up results of two randomised controlled trials","volume":"14","author":"Haviland","year":"2013","journal-title":"Lancet Oncol"},{"key":"2025052713263508300_tqaf056-B20","doi-asserted-by":"crossref","first-page":"1613","DOI":"10.1016\/S0140-6736(20)30932-6","article-title":"Hypofractionated breast radiotherapy for 1 week versus 3 weeks (FAST-Forward): 5-year efficacy and late normal tissue effects results from a multicentre, non-inferiority, randomised, phase 3 trial","volume":"395","author":"Murray Brunt","year":"2020","journal-title":"Lancet"},{"key":"2025052713263508300_tqaf056-B21","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S1470-2045(08)70077-9","article-title":"The UK Standardisation of Breast Radiotherapy (START) Trial A of radiotherapy hypofractionation for treatment of early breast cancer: a randomised trial","volume":"9","author":"Bentzen","year":"2008","journal-title":"Lancet Oncol"},{"key":"2025052713263508300_tqaf056-B22","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.radonc.2005.01.005","article-title":"Fractionation sensitivity and dose response of late adverse effects in the breast after radiotherapy for early breast cancer: long-term results of a randomised trial","volume":"75","author":"Yarnold","year":"2005","journal-title":"Radiother Oncol"},{"key":"2025052713263508300_tqaf056-B23","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3390\/jpm10040155","article-title":"Radiation biomarkers in large scale human health effects studies","volume":"10","author":"Moquet","year":"2020","journal-title":"J Pers Med"},{"issue":"9","key":"2025052713263508300_tqaf056-B24","doi-asserted-by":"crossref","first-page":"e25113","DOI":"10.1371\/journal.pone.0025113","article-title":"Gamma-H2AX-based dose estimation for whole and partial body radiation exposure","volume":"6","author":"Horn","year":"2011","journal-title":"PLoS One"},{"key":"2025052713263508300_tqaf056-B25","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1158\/1078-0432.CCR-18-0777","article-title":"Association of CD4(+) radiation-induced lymphocyte apoptosis with fibrosis and telangiectasia after radiotherapy in 272 breast cancer patients with &gt;10-year follow-up","volume":"25","author":"Veldwijk","year":"2019","journal-title":"Clin Cancer Res"},{"key":"2025052713263508300_tqaf056-B26","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0167-8140(19)31067-9","article-title":"Analysis of biomarkers for late radiotherapy toxicity in the REQUITE project","author":"Talbot","year":"2019","journal-title":"Radiother Oncol"},{"key":"2025052713263508300_tqaf056-B27","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.radonc.2019.04.034","article-title":"REQUITE: a prospective multicentre cohort study of patients undergoing radiotherapy for breast, lung or prostate cancer","volume":"138","author":"Seibold","year":"2019","journal-title":"Radiother Oncol"},{"key":"2025052713263508300_tqaf056-B28","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1016\/j.ijrobp.2014.01.002","article-title":"Relationship between radiation-induced apoptosis of T lymphocytes and chronic toxicity in patients with prostate cancer treated by radiation therapy: a prospective study","volume":"88","author":"Foro","year":"2014","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025052713263508300_tqaf056-B29","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1748-717X-5-4","article-title":"Prediction of clinical toxicity in locally advanced head and neck cancer patients by radio-induced apoptosis in peripheral blood lymphocytes (PBLs)","volume":"5","author":"Bordon","year":"2010","journal-title":"Radiat Oncol"},{"key":"2025052713263508300_tqaf056-B30","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3109\/09553002.2010.537433","article-title":"Role of CD4 and CD8 T-lymphocytes, B-lymphocytes and natural killer cells in the prediction of radiation-induced late toxicity in cervical cancer patients","volume":"87","author":"Bord\u00f3n","year":"2011","journal-title":"Int J Radiat Biol"},{"key":"2025052713263508300_tqaf056-B31","doi-asserted-by":"crossref","first-page":"220","DOI":"10.3390\/antiox9030220","article-title":"The possibility of using genotoxicity, oxidative stress and inflammation blood biomarkers to predict the occurrence of late cutaneous side effects after radiotherapy","volume":"9","author":"Chaouni","year":"2020","journal-title":"Antioxidants"},{"key":"2025052713263508300_tqaf056-B32","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/j.clon.2014.09.008","article-title":"The REQUITE project: validating predictive models and biomarkers of radiotherapy toxicity to reduce side-effects and improve quality of life in cancer survivors","volume":"26","author":"West","year":"2014","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2025052713263508300_tqaf056-B33","doi-asserted-by":"crossref","first-page":"6284","DOI":"10.1158\/1078-0432.CCR-08-0700","article-title":"Single nucleotide polymorphisms, apoptosis, and the development of severe late adverse effects after radiotherapy","volume":"14","author":"Azria","year":"2008","journal-title":"Clin Cancer Res"},{"key":"2025052713263508300_tqaf056-B34","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1093\/jnci\/djz075","article-title":"Radiogenomics consortium genome-wide association study meta-analysis of late toxicity after prostate cancer radiotherapy","volume":"112","author":"Kerns","year":"2020","journal-title":"J Natl Cancer Inst"},{"key":"2025052713263508300_tqaf056-B35","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.radonc.2021.03.024","article-title":"Development of a method for generating SNP interaction-aware polygenic risk scores for radiotherapy toxicity","volume":"159","author":"Franco","year":"2021","journal-title":"Radiother Oncol"},{"key":"2025052713263508300_tqaf056-B36","doi-asserted-by":"crossref","first-page":"541281","DOI":"10.3389\/fonc.2020.541281","article-title":"A deep learning approach validates genetic risk factors for late toxicity after prostate cancer radiotherapy in a REQUITE multi-national cohort","volume":"10","author":"Massi","year":"2020","journal-title":"Front Oncol"},{"key":"2025052713263508300_tqaf056-B37","doi-asserted-by":"crossref","first-page":"83","DOI":"10.3389\/fonc.2017.00083","article-title":"Data-based radiation oncology: design of clinical trials in the toxicity biomarkers era","volume":"7","author":"Azria","year":"2017","journal-title":"Front Oncol"},{"key":"2025052713263508300_tqaf056-B38","doi-asserted-by":"crossref","first-page":"1048","DOI":"10.1016\/S0140-6736(17)31145-5","article-title":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial","volume":"390","author":"Coles","year":"2017","journal-title":"Lancet"},{"key":"2025052713263508300_tqaf056-B39","doi-asserted-by":"crossref","first-page":"867","DOI":"10.1016\/j.ijrobp.2021.07.003","article-title":"Patterns of care, tolerability, and safety of the first cohort of patients treated on a novel high-field MR-linac within the MOMENTUM study: initial results from a prospective multi-institutional registry","volume":"111","author":"de Mol van Otterloo","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"2025052713263508300_tqaf056-B40","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1186\/1748-717X-5-85","article-title":"Radiation induced apoptosis and initial DNA damage are inversely related in locally advanced breast cancer patients","volume":"5","author":"Pinar","year":"2010","journal-title":"Radiat Oncol"},{"key":"2025052713263508300_tqaf056-B41","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S1470-2045(09)70382-1","article-title":"Comparison of patient-reported breast, arm, and shoulder symptoms and body image after radiotherapy for early breast cancer: 5-year follow-up in the randomised Standardisation of Breast Radiotherapy (START) trials","volume":"11","author":"Hopwood","year":"2010","journal-title":"Lancet Oncol"},{"key":"2025052713263508300_tqaf056-B42","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.clon.2016.01.011","article-title":"Do patient-reported outcome measures agree with clinical and photographic assessments of normal tissue effects after breast radiotherapy? The experience of the Standardisation of Breast Radiotherapy (START) trials in early breast cancer","volume":"28","author":"Haviland","year":"2016","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"2025052713263508300_tqaf056-B43","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.radonc.2010.09.002","article-title":"Pathogenetic mechanisms in radiation fibrosis","volume":"97","author":"Yarnold","year":"2010","journal-title":"Radiother Oncol"}],"container-title":["British Journal of Radiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/bjr\/advance-article-pdf\/doi\/10.1093\/bjr\/tqaf056\/62402861\/tqaf056.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/98\/1170\/929\/62402861\/tqaf056.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjr\/article-pdf\/98\/1170\/929\/62402861\/tqaf056.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,27]],"date-time":"2025-05-27T17:26:50Z","timestamp":1748366810000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjr\/article\/98\/1170\/929\/8075126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,13]]},"references-count":43,"journal-issue":{"issue":"1170","published-online":{"date-parts":[[2025,3,13]]},"published-print":{"date-parts":[[2025,6,1]]}},"URL":"https:\/\/doi.org\/10.1093\/bjr\/tqaf056","relation":{},"ISSN":["0007-1285","1748-880X"],"issn-type":[{"value":"0007-1285","type":"print"},{"value":"1748-880X","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,6]]},"published":{"date-parts":[[2025,3,13]]}}}